For how we live.
I-SPY2.2 tested trastuzumab-deruxtecan plus rilvegostomig before surgery in high-risk HER2-negative breast cancer. In immune-positive tumours 54% had a complete response, and most of them avoided anthracyclines.
A Global Burden of Disease analysis finds the share of female breast-cancer deaths tied to high fasting plasma glucose rose from 1990 to 2023 and is projected to keep rising — but the design cannot prove causation.
In 1,429 high-risk breast-cancer patients, a 16-dose regimen covering the internal mammary nodes matched the standard 25-dose course for recurrence and caused far less severe skin damage.
Among 84 women on aromatase inhibitors, CO2 laser did no better than a fake laser for sexual function at 12 months. Both groups improved — on moisturisers and vibrators given to everyone.
The pill joins trastuzumab and pertuzumab as maintenance after induction. In the 654-patient HER2CLIMB-05 trial it stretched median progression-free survival to 24.9 months from 16.3, a hazard ratio of 0.64.
The phase 3 RT CHARM trial found a three-week course of radiation after mastectomy was no worse than the standard five-week course for reconstruction complications, at 12.3% versus 10.2%.
In the industry-funded evERA trial, giredestrant plus everolimus delayed progression of ER-positive breast cancer — but the clearest benefit was in ESR1-mutated tumours, and the endpoint was a surrogate, not survival.
Final results of the phase 3 IMpassion050 trial show adding the immunotherapy atezolizumab to standard HER2-targeted treatment did not improve event-free or disease-free survival.
Eli Lilly's oral Inluriyo gained an FDA efficacy supplement on 18 September. In the phase 3 EMBER-3 trial, adding abemaciclib lifted median progression-free survival to 9.4 months from 5.5.
Most lumps are not cancer — swollen glands usually signal infection, and most breast changes are benign. A few features shift the calculus: hard, fixed, growing, or paired with night sweats or weight loss.
A pooled study of 1.44 million adults links activity to lower risk of 13 cancers — but not all, and not melanoma. A 2025 randomised trial now shows exercise after colon cancer improves survival.
Manual lymphatic drainage is a real physiotherapy for swelling after breast-cancer treatment, where trials show modest, mixed benefit. For 'detoxing' or slimming a healthy body there is no evidence.
The fear that soy fuels breast cancer is not supported by the human data; if anything, soy food intake tracks with lower recurrence and death after diagnosis. Its other health claims are weaker.
Men are under 1% of breast-cancer cases, but they present older and at higher stage, and survival has improved more slowly than in women. Care is largely borrowed from female breast cancer.
A cohort of 5.24 million UK adults linked higher BMI to 17 of 22 cancers — strongly for the uterus, weakly or not at all for others, and inversely for a couple. The pattern is specific, not uniform.
23andMe's cleared BRCA report reads 3 of more than 1,000 mutations, so a negative result is not the all-clear it looks like — and the firm's bankruptcy has put customers' genetic data in play.
The first randomised trial to report interval cancers found AI non-inferior to double reading, with higher sensitivity at equal specificity. Across three European programmes the extra detection is about one per 1000.
SERENA-6 changed therapy the moment a resistance mutation appeared in the blood, not when tumours grew. It nearly doubled time to progression — and won camizestrant FDA approval in 2026.
In the NSABP B-59 trial, adding the immunotherapy to neoadjuvant chemotherapy did not significantly improve event-free survival, while immune-related side effects more than doubled.
Dense tissue raises breast-cancer risk and hides cancers on a mammogram. US facilities must now tell patients — but the evidence on what to do next is a real trade-off: more cancers found, more false alarms.
SleepCARE randomised 219 Australian women receiving chemotherapy for breast cancer to CBT-I, bright light therapy, both, or sleep hygiene. Only CBT-I moved insomnia — and nothing moved fatigue.
Six products got revised labels in February 2026, removing cardiovascular, breast cancer, and dementia language. The scientific societies that welcomed the change also listed the distinctions the new label does not make.
US guidance recommends mammography from 40. A Canadian review of the same randomised evidence put the benefit at 0.27 fewer breast cancer deaths per 1,000 women aged 40-49 over ten years.
The IARC calls night shift work probably carcinogenic. A 2026 meta-analysis of nurses shows why 'probably' is careful: the breast cancer signal appears only after decades, and shrinks to nothing once bias is corrected.
A 2025 US Surgeon General advisory put alcohol third among preventable causes of cancer. The global data show light drinking contributes too, not only heavy use.
A comparative survey finds four European countries still rely on opportunistic screening, and that where family doctors are most involved, participation tends to be lower — not higher.
The VEMORA trial randomized 23 women with genitourinary symptoms. Vaginal estrogen improved dryness and pain scores more than Replens, with blood estrogen staying low.
A Finnish registry of over 123,000 women found pre-eclampsia linked to an 11% lower breast cancer risk decades later. Hormone therapy raised risk by a similar amount in both groups.
A comparison of FDA, EMA and ANVISA decisions from 2020 to 2024 finds Brazilian approvals arriving about a year later. A second study clocks the wait for public-system financing in years, not months.
An age-period-cohort analysis across five registries finds annual increases of 5.3% in Korea and 3.8% in Japan, against 1.6% among Japanese Americans and flat or falling rates in US White women.
In VERITAC-2 the oral degrader more than doubled progression-free survival over fulvestrant in patients with an ESR1 mutation — 5.0 months versus 2.1 — but not in the trial as a whole.
Women whose habits aligned with a favorable estrogen-metabolism pathway had up to 61% lower endometrial cancer risk. The score explains only a tenth of the variation it predicts.
Pooling decades of research, the combined estrogen-progestin regimen showed a 44% higher breast cancer risk. Estrogen-only therapy showed none in observational studies — and trials suggested it lowered risk.
A Taiwanese cohort of 26,000 women aged 20 to 50 puts numbers on a known tamoxifen risk in a population — younger, premenopausal — where data has been thinner.
In 105,260 people followed for 7.6 years, higher intakes of sorbates, sulfites, nitrates and acetates tracked with modestly higher cancer incidence. This is an observational study of self-reported diets.
The consensus statement does not claim the treatment is safe after breast cancer. It says some women may reasonably accept an increased relapse risk in exchange for symptom relief.
In the phase 3 ASCENT-04 trial, sacituzumab govitecan with pembrolizumab lifted median progression-free survival to 11.2 months from 7.8 in PD-L1-positive disease. Survival data are immature.
WISDOM randomised 28,372 women to annual mammography or a risk-tailored schedule. The risk-based arm met its non-inferiority mark for advanced cancers — with caveats about who enrolled.
VENUSCANCER assembled individual records for 275,792 women from 103 cancer registries in 39 countries. The gaps it found are in what treatment women actually received, not only in whether they were diagnosed.
Age-standardised incidence was 42.3 per 100,000 in Ghana and 43.1 in US non-Hispanic Black women, against 24.0 in white women. ER-positive rates diverged sharply in the other direction.